PuSH - Publication Server of Helmholtz Zentrum München

From basic science to diagnostics - History of a patent on a honeybee venom allergen.

Allergy 74, 385-387 (2019)
Publ. Version/Full Text Postprint DOI
Open Access Green
Hymenoptera venom can induce severe IgE-mediated systemic and even fatal allergic reactions. Fortunately, venom-specific immunotherapy (VIT) is one of the most effective disease-modifying curative treatments in the field of clinical allergology, but choosing the correct venom for VIT represents a crucial prerequisite for effective protection. In the past, therapeutic decisions based on specific IgE (sIgE) levels to whole venom extracts were not always straightforward. The presence of cross-reactive allergens and cross-reactive carbohydrate determinants (CCDs) in the extracts complicated the discrimination between cross-reactivity and true allergy to more than one venom. In the last years, the increasing knowledge of the composition of relevant venom allergens and the availability of recombinant CCD-free marker allergens resulted in the development of an advanced component-resolved diagnostics (CRD) of venom allergy. CRD has increased the sensitivity of sIgE detection and enabled the discrimination between primary sensitization and cross-reactivity, particularly in patients double-sensitized to honeybee and vespid venom.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Bee
ISSN (print) / ISBN 0105-4538
e-ISSN 1398-9995
Journal Allergy
Quellenangaben Volume: 74, Issue: 2, Pages: 385-387 Article Number: , Supplement: ,
Publisher Wiley
Publishing Place 111 River St, Hoboken 07030-5774, Nj Usa
Reviewing status Peer reviewed